Abstract
Caution should always be exercised in considering early termination for any randomized clinical trial not only to avoid reacting to a temporary trend in the data, but also to avoid the loss of important treatment information concerning secondary outcomes, key subgroups, and patient safety data. For the Heart Outcomes Prevention Evaluation (HOPE) and Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trials, their Data and Safety Monitoring Boards (DSMBs) ensured that this information was complete prior to making their decisions. For the HOPE trial, the DSMB did unblind the principal investigator early, who agreed with their assessment and stopped the trial before its scheduled conclusion. For CURE trial, the DSMB decided not to recommend early termination but allowed the trial to continue to collect important safety data to its planned end. DSMBs play a vital role in ensuring that information that effects clinical practice is ultimately obtained.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The HOPE Study Investigators. 1996. The HOPE (Heart Outcomes Prevention Evaluation) Study:The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at risk of cardiovascular events. Can J Cardiol 12:127–137.
The Heart Outcomes Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153.
The Heart Outcomes Prevention Evaluation Study Investigators. 2000. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342:154–160.
CURE Study Investigators. 2000. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme: Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 21:2033–2041.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502.
Haybittle, JL. 1971. Repeated assessment of results in clinical trials of cancer treatment. B J Radiol 44:793–797.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. 1976. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I. Introduction and design. Br J Cancer 34:585–612.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Pogue, J., Sackett, D., Wyse, D.G., Yusuf, S. (2006). Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials: Avoiding Important Information Loss. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_14
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_14
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)